Lv6
1690 积分 2021-03-29 加入
Development issues: antibody stability, developability, immunogenicity, and comparability
1天前
已完结
FDA Approval Summary: Datopotamab Deruxtecan-dlnk for Treatment of Patients with Unresectable or Metastatic, HR-Positive, HER2-Negative Breast Cancer
2天前
已完结
Mapping the patent landscape of TROP2-targeted biologics through deep learning
3天前
已完结
Cloning of the gene encoding TROP‐2, a cell‐surface glycoprotein expressed by human carcinomas
4天前
已完结
Biochemical Characterization of Trop-2, a Cell Surface Molecule Expressed by Human Carcinomas: Formal Proof that the Monoclonal Antibodies T16 and MOv-16 Recognize Trop-2
4天前
已完结
Targeting TROP2 Across Solid Tumors: The Clinical Profile and Role of Datopotamab Deruxtecan
6天前
已完结
Recent advances in trophoblast cell‐surface antigen 2 targeted therapy for solid tumors
6天前
已完结
Daraxonrasib in Previously Treated Advanced RAS -Mutated Pancreatic Cancer
6天前
已完结
Chemical remodeling of a cellular chaperone to target the active state of mutant KRAS
8天前
已完结
皖公网安备34019202002308
